home
features
applications
community
stories
news

Menu

home
features
applications
community
stories
news

Congratulations to Sarah Merkling (Pasteur Institute) for her recent Single-Cell Publication.

mars 1, 2021
, 8:28
, news

SuivantRNAssist Limited and QCMD Agree Collaboration for vivoPHIX™ Biomolecule Stabilization TechnologySuivant

Share this post

Partager sur facebook

Partager sur twitter

Partager sur linkedin

Partager sur pinterest

Partager sur print

Partager sur email

Contact us

If you would like to receive news about RNAssist and associated products, evaluate our ground-breaking fixative and stabiliser, carryout tissue dissociation and single-cell preparation or would simply like to exchange comments and results with more than 180 other members of the RNAssist User Community please send a message. We look forward to meeting you!

Your Name

Your Email

Your message

vivoPHIX™, genoPHIX™, virusPHIX™ and virusPHIX-P9™ , as well as virus and viral inactivation, virus transport media (VTM), SARS-CoV-2, Covid-19, diagnostics, biosafety, LAMP testing, Lateral Flow, Antigen, Serology, antibody testing, immunofluorescence, scRNA-seq, scDNA-seq, tissue dissociation, saliva, swab, blood, plasma, EQA and molecular controls .

This non-toxic formalin-free tissue fixative ensures the preservation of both tissue histomorphology and biomolecules. RNAssist prevents the degradation of proteins, DNA, RNA and mRNA. When compared to products such as RNAlater ®, PAXgene Tissue Systems or Allprotect ® Tissue Reagent, RNA demonstrated high-quality RNA stabilization and protection in the context of long-term tissue storage and archival . Designed for room temperature use, RNAssist is compatible with routine paraffin-embedding procedure, pathology staining – (H&E, immunohistochemistry (IHC) , in situ hybridization (IS) – and molecular analysis : RT-PCR, WB, next-geneneration sequencing, …